| Date | Title | Description |
| 16.12.2025 | Enginprime Medical Inc Announces First-in-Human Study of Its Leading OpusOne™ pVAD | HANGZHOU, China, Dec. 16, 2025 /PRNewswire/ -- Enginprime Medical Inc ("Enginprime"), an emerging leader in percutaneous ventricular assist device (pVAD) technologies and a Voyagers Capital portfolio company, today announced that ... |
| 29.08.2024 | The Surge of Cardiac Surgery: A Market in Motion | The global cardiac surgery market is on the rise. It’s a lifeline in a world grappling with cardiovascular diseases (CVDs). These diseases are silent killers, claiming over 17 million lives each year. As technology advances, the market is p... |
| 28.08.2024 | Cardiac Surgery Market to Exceed $24B Due to Global Shift Towards Minimally Invasive Surgeries (TAVI/TAVR and TMVr) | iData Research | VANCOUVER, BC, Aug. 28, 2024 /PRNewswire/ - In a world, where cardiovascular diseases (CVDs) remain a leading cause of death, the global cardiac surgery market has emerged as a cornerstone of life-saving interventions, driven by innovations... |
| 21.08.2024 | Health | The FDA calls them ‘recalls,’ yet the targeted medical devices often remain in use | “It’s very oxymoronic,” said Rita Redberg, a cardiologist at the University of California, San Francisco and former editor in chief of the journal JAMA Internal Medicine. “A recall makes it sound like it’s recalled. But that is not actually... |
| 12.08.2024 | Heart Pump Recall: Abiomed Removes Certain Impella CP with SmartAssist Systems due to Failed Quality Inspections | This recall involves removing certain devices from where they are used or sold. The FDA has identified this recall as the most serious type. This device may cause serious injury or death if you continue to use it. Affected Product
Product N... |
| 11.04.2024 | Randomized controlled trial confirms that Impella CP(R) improves survival in patients with ST-segment elevation myocardial infarction accompanied by cardiogenic shock | Randomized controlled trial confirms that Impella CP(R) improves survival in patients with ST-segment elevation myocardial infarction accompanied by cardiogenic shock
*View in browser* *Japan Abiomed*
Press release: April 11, 2024
**
Random... |
| 11.04.2024 | Randomized controlled trial confirms that Impella CP(R) improves survival in patients with ST-segment elevation myocardial infarction accompanied by cardiogenic shock | - |
| 27.02.2024 | Germfree Announces the Appointment of Four Independent Board Members | Feb 27 2024
Ormond Beach, Florida – Germfree announces the appointments of Dorothy Puhy, Karen Flynn, Kerry Ingalls and Helga Salling as independent non-executive members of its Board of Directors.
“We are excited to welcome Dorothy, Kare... |
| 03.05.2023 | Magenta Medical Rakes In $55M for ‘World’s Smallest Heart Pump’ | Magenta Medical — an Israeli company developing what it bills as “the world’s smallest heart pump” — closed a $55 million financing round on Wednesday.
The round was led by OrbiMed, with participation from New Enterprise Associates, Pitango... |
| 05.12.2022 |
FDA tightens indications for Abiomed Impella RP system | The Impella RP Flex with SmartAssist. [Image from Abiomed]The FDA announced today that it is updating the labeling on Abiomed‘s Impella RP system to reflect the final post-approval study results.
Abiomed announced in October that FDA had ap... |
| 19.09.2022 | Abbott’s HeartMate 3 extends life by 5 years for advanced heart failure patients | When Dr. Robert Kormos, a cardiothoracic surgeon, began his career 30 years ago, he would dream of extending the lives of his patients who were often battling advanced heart failure. Now, as division vice president of medical device company... |
| 03.02.2022 | ABIOMED : ANNOUNCES RECORD REVENUE OF $261 MILLION, UP 13% YEAR OVER YEAR - Form 8-K | ABIOMED ANNOUNCES RECORD REVENUE OF $261 MILLION, UP 13% YEAR OVER YEAR
Increasing Low End of Guidance: $1,025 Million - $1,030 Million, up 21% - 22%
Danvers, Mass. - February 3, 2022 - ABIOMED, Inc. (NASDAQ: ABMD), a leading provider of br... |
| 03.02.2022 | Abiomed Announces Record Revenue of $261 Million, up 13% Year Over Year | ABIOMED, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced financial results for the quarter ended December 31, 2021.
Q3 financial summary and operational highlights:
Revenue for the quarter... |
| 10.01.2022 | Abiomed picks up regulatory wins in U.S., Asia | This illustration shows the Impella 5.5 with SmartAssist placed in the heart. [Image courtesy of Abiomed]Abiomed (NSDQ:ABMD) announced today that regulators in three different countries granted new approvals to Impella surgical products.
Da... |
| 18.11.2021 | QAD : Navigating Disruption in MedTech | "Our biggest challenge was not maintaining production and operations during the pandemic - but it's today, managing the impact of the aftershocks."- Joanne Mavroides, Director Supply Chain & Logistics at Abiomed
The medtech in... |
| 28.10.2021 | Abiomed Announces Q2 FY 2022 Revenue of $248 Million, Up 18% Year Over Year | Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced financial results for the quarter ended September 30, 2021.
Q2 financial summary and operational highlights:
Revenue for the quarter... |
| 28.10.2021 | ABIOMED ANNOUNCES Q2 FY 2022 REVENUE OF $248 MILLION, UP 18% YEAR OVER YEAR - Form 8-K | ABIOMED ANNOUNCES Q2 FY 2022 REVENUE OF $248 MILLION, UP 18% YEAR OVER YEAR
DANVERS, Mass. - October 28, 2021 - ABIOMED, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced financial results f... |
| 05.08.2021 | ABIOMED : ANNOUNCES RECORD REVENUE OF $253 MILLION, UP 53% YEAR OVER YEAR (Form 8-K) | ABIOMED ANNOUNCES RECORD REVENUE OF $253 MILLION, UP 53% YEAR OVER YEAR
Full year global revenue guidance increased for fiscal year 2022 to 22% - 24% growth versus prior year
DANVERS, Mass. - August 4, 2021 - Abiomed, Inc. (NASDAQ: ABMD),... |
| 04.08.2021 | Abiomed : Announces Record Revenue of $253 Million, Up 53% Year Over Year | Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced financial results for the quarter ended June 30, 2021.
Q1 financial summary and operational highlights:
Total revenue for the quart... |
| 29.04.2021 | ABIOMED, INC.
Abiomed : Announces Record Revenue of $241 Million, up 17% Year Over Year, With 26.0% Operating Margin | Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies today reported record fourth quarter fiscal 2021 revenue of $241.2 million compared to revenue of $206.7 million for the same period of fiscal 2020,... |
| 06.08.2020 | Abiomed : Announces Q1 FY 2021 Revenue of $165 Million and 21% Operating Margin | Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies today reported first quarter fiscal 2021 revenue of $164.9 million compared to revenue of $207.7 million for the same period of fiscal 2020 despite ... |
| 05.10.2017 | Israeli medtech firm raised $15M to treat heart-failure patients with catheter-based therapy | Founded in October 2012 by a cardiologist and a mechanical engineer, Magenta Medical raised $15 million last week. Investors include medical device company Abiomed; Pitango Venture Capital, an Israeli fund; JAFCO, a Japanese private equity ... |
| 27.07.2017 | Abiomed Announces Q1 FY 2018 Revenue of $132.5 Million, Up 29% Over Prior Year | Jul 27 2017
DANVERS, Massachusetts— Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today reported first quarter fiscal 2018 revenue of $132.5 million, an increase of 29% compared to revenue of ... |
| 11.11.2016 | Military Business Advantage: the new MBA for the life sciences | On today’s military battlefields, the United States is fighting asymmetric wars. Traditionally trained forces face insurgencies with seeming limitless capacity for unconventional campaigns. The old top-down warfare model, where a general de... |
| 04.02.2016 | Abiomed Announces Q3 FY 2016 Revenue of $85.8 Million, Up 38% Over Prior Year | Feb 04 2016
DANVERS, Massachusetts—Abiomed (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today reported third quarter fiscal 2016 revenue of $85.8 million, an increase of 38% compared to revenue of $62.0 mi... |
| 11.01.2016 | Abiomed Announces Preliminary Q3 FY 2016 Revenue of $85.8 Million, Up 38% Over Prior Year | Jan 11 2016
SAN FRANCISCO, CA.—Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today reported preliminary unaudited third quarter fiscal 2016 revenue of approximately $85.8 million, an increase ... |
| 04.08.2015 | Abiomed Announces Q1 FY 2016 Revenue of $73.4 Million, Up 50% Over Prior Year | Aug 04 2015
DANVERS, Massachusetts—Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today reported first quarter fiscal 2016 revenue of $73.4 million, an increase of 50% compared to revenue of $4... |
| 14.10.2014 | Syncardia ramping up production of its total artificial heart | The workings of Syncardia’s CardioWest heart are actually outlined nicely by NIH:
A TAH usually extends life for months beyond what is expected with end-stage heart failure. If you’re waiting for a heart transplant, a TAH can keep you alive... |
| 22.11.2013 | Boston Scientific appoints new investor relations VP | Michael Campbell is the current VP of investor relations at BSX. He’s been with the company more than a decade.
On Oct. 24, the medical device company announced a restructuring plan that included naming a new CFO who will begin Jan. 1, and ... |
| 26.08.2013 | ‘World’s smallest heart pump’ company lands big government contract with VA | Promoted
Covid-19’s terrible toll on diabetes patients. What can be done?
The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| 17.06.2013 | Medical Devices: What does it really mean to be disruptive? | By Amy Siegel & Tim Kofol, S2N Health
In our line of work, we come across many innovative medical technologies appended with the adjective “disruptive” but some uses of the term require more squinting to imagine than others.
The disrupt... |
| 11.11.2012 | Soldiers-turned-CEOs: 5 healthcare companies with U.S. military veterans in the top seat | What do Johnson & Johnson, FedEx and Verizon Communications have in common? Aside from being Fortune 500 companies, they’re also led by former members of the U.S. military.
According to a new Kauffman Foundation study just released, vet... |
| 07.01.2010 | Abiomed’s preliminary Q3 revenues jump 32 percent | Abiomed Inc.’s (NSDQ:ABMD) Impella cardiac assist device is turning into a star for the Danvers, Mass.-based company, which said preliminary third-quarter sales jumped 32 percent.
That’s largely due to the Impella device, a tiny pump that’s... |
| 30.03.2009 | Essex Woodlands raises almost $1B for life science investments | Essex Woodlands Health Ventures announced today that it brought in $900 million for its eighth fund, one of the largest sums ever raised by a health care-focused venture firm, according to the Wall Street Journal — even more impressive cons... |
| - | Israeli medtech firm raised $15M to treat heart-failure patients with catheter-based therapy | Acute heart failure affects about 6.5 million people in the United States, with 960,000 new cases diagnosed annually, based on data from the American Heart Association.
Executives at Israel-based Magenta Medical believe that the company’s c... |
| - | Johnson & Johnson beats on earnings and revenue, raises full-year guidance | Johnson & Johnson reported adjusted earnings and revenue that beat expectations, and raised its full-year guidance, citing strength in units including pharmaceuticals.
J&J, whose financial results are considered a bellwether for man... |
| - | ‘World’s smallest heart pump’ company lands big government contract with VA | The product Abiomed (ABMD) has deemed to be the “world’s smallest heart pump” will be included on the Veterans Affairs‘ Federal Supply Schedule. The Danvers, Mass.-based announced today it’s landed a federal contract to make its Impella pla... |
| - | Syncardia ramping up production of its total artificial heart | To keep up with the demand for its total artificial heart, Tucson-based Syncardia is in the midst of a Series F funding round, a spokesman said.
This isn’t new technology. The company’s had Food and Drug Administration approval for the devi... |
| - | Soldiers-turned-CEOs: 5 healthcare companies with U.S. military veterans in the top seat | What do Johnson & Johnson, FedEx and Verizon Communications have in common? Aside from being Fortune 500 companies, they’re also led by former members of the U.S. military.
According to a new Kauffman Foundation study just released, vet... |
| - | Boston Scientific appoints new investor relations VP | Boston Scientific (BSX) has taken its new investor relations VP from Abiomed (ABMD), the company known for the world’s smallest heart pump and AbioCor. Susan Lisa has served as the senior director of investor relations and corporate develop... |
